Cefipime: Difference between revisions
Annhuang04 (talk | contribs) |
Annhuang04 (talk | contribs) |
||
| Line 17: | Line 17: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
====infection, bacterial==== | |||
>2 months<br /> | |||
50mg/kg IV/IM q12hr, max 2g/dose | |||
====febrile neutropenia==== | |||
>2 months<br /> | |||
50mg/kg IV/IM q8h; max 2g/dose | |||
====resp. infection, cystic fibrosis pts==== | |||
> 2 months<br /> | |||
50mg/kg IV/IM q8h; max 2g/dose | |||
==Special Populations== | ==Special Populations== | ||
Revision as of 00:39, 3 September 2015
General
- Type: cephalosporin (4th generation)
- Dosage Forms: IM/IV
- Common Trade Names: Maxipime
Adult Dosing
- 1-2 g IV q12h
febrile neutropenia
- 2g IV q8h
UTI, mild-mod
- 0.5g - 1g q12h x 7-10days
UTI, severe
- 2g IV q12h x 10days
Pediatric Dosing
infection, bacterial
>2 months
50mg/kg IV/IM q12hr, max 2g/dose
febrile neutropenia
>2 months
50mg/kg IV/IM q8h; max 2g/dose
resp. infection, cystic fibrosis pts
> 2 months
50mg/kg IV/IM q8h; max 2g/dose
Special Populations
- Pregnancy:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
